Stay up to date on our announcements, media coverage, and resources.

Press releases and statements

Our latest company updates, product launches, leadership announcements, and public statements.

Recent highlights

Celltrion to Present New Analyses of OMLYCLO® (omalizumab-igec) in Chronic Spontaneous Urticaria at ACAAI 2026

Read more

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026

Read more

Celltrion in the News

Celltrion USA has signed a contract with Ventegra® to add Yuflyma® (adalimumab-aaty) as a preferred formulary product in both public and private insurance markets

Celltrion USA has signed a contract with Ventegra® to add Yuflyma® (adalimumab-aaty) as a preferred formulary product in both public and private insurance markets – By inclusion in Ventegra’s formularies, Yuflyma® has secured access through the appropriate channel for about 3.6% of the U.S. population October 05, 2023 04:52 PM Eastern Daylight Time JERSEY CITY, N.J.–(BUSINESS WIRE)–Celltrion USA has […]
Read more

Celltrion USA launches Yuflyma® (adalimumab-aaty), a Humira® (adalimumab) biosimilar, in the United States

Celltrion USA launches Yuflyma® (adalimumab-aaty), a Humira® (adalimumab) biosimilar, in the United States Yuflyma is Celltrion USA’s high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar   JERSEY CITY, N.J.–Celltrion USA today announced the launch of Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, providing an alternative option for patients. Yuflyma is indicated […]
Read more

Celltrion USA Announces U.S. FDA Approval of Yuflyma® (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira® (adalimumab) Biosimilar

Celltrion USA Announces U.S. FDA Approval of Yuflyma® (adalimumab-aaty),  a High-Concentration and Citrate-Free Formulation of Humira® (adalimumab) Biosimilar Yuflyma is FDA approved to treat eight conditions including Crohn’s disease and ulcerative colitis Yuflyma is the first high-concentration and citrate-free adalimumab biosimilar to gain EU marketing authorization Yuflyma offers citrate-free and high-concentration adalimumab formulation, providing an alternative treatment […]
Read more

Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer

 Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer   Seasoned commercial operations executive brings three decades of global biopharmaceutical industry experience to Celltrion USA’s leadership team   February 06, 2023, CHICAGO, IL –Celltrion USA, a global leader in expanding access to innovative biologics, today announced the appointment of Thomas Nusbickel as Chief Commercial Officer.  Mr. Nusbickel will oversee […]
Read more

Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration

Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration     CT-P13 SC is a novel subcutaneous formulation of infliximab The Biologics License Application (BLA) submission is based on phase III pivotal data that evaluated the efficacy and safety of CT-P13 SC […]
Read more

Celltrion USA receives U.S. FDA approval for its oncology biosimilar Vegzelma® (bevacizumab-adcd) for the treatment of six types of cancer

Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma® (bevacizumab-adcd) for the Treatment of Six Types of Cancer Vegzelma® is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma® offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option The approval is based on totality of evidence […]
Read more

Media asset library

Assets and resources for journalists, partners, and stakeholders.

Access assets